Health and Human Services Secretary Robert F. Kennedy Jr. announced this week that the Food and Drug Administration will reexamine the abortion pill mifepristone, triggering debate over the future of medication abortion access in the United States.

ABC News reported that the decision follows a request by 22 Republican attorneys general and has raised new concerns among abortion rights supporters about the potential for stricter controls on the country’s most widely used method of abortion.

The formal announcement arrived in a joint letter issued by Secretary Kennedy and FDA Commissioner Marty Makary. The letter was addressed to the officials who had petitioned for a reassessment of the drug’s safety and administration protocols.

Medication abortion has grown into the predominant method of terminating pregnancies in the U.S. According to the Guttmacher Institute, it accounts for nearly two-thirds of all abortion procedures nationwide.

Mifepristone, approved by the FDA in 2000, is commonly used in combination with misoprostol to end early pregnancies or manage miscarriages. The drug functions by blocking progesterone, a hormone required to sustain pregnancy.

Review Triggered by Political and Scientific Debate

The call for review emerged following the publication of a conservative-affiliated study by the Ethics and Public Policy Center. The study, referenced by Kennedy and other officials, claimed that nearly 11% of women experienced severe complications after using mifepristone.

This figure stands in stark contrast to the FDA’s own data, which cites a 0.5% rate for serious adverse events. Critics have pointed out that the study has not undergone peer review and was only published on the center’s website.

During a Senate Finance Committee hearing on Sept. 4, Kennedy described the findings of the report as “alarming.” He stated that, in light of the data, he believed the drug's labeling should, at a minimum, be updated.

Debate Over Public Health and Political Influence

Despite initiating the review, Kennedy has not committed his agency to any regulatory changes as of now. Instead, he has tasked Commissioner Makary with conducting a full examination and reporting the findings back to him.

The letter from Kennedy and Makary emphasized that the concerns brought forth “merit close examination” and assured that women’s health would remain a key focus of the investigation.

Abortion rights groups, however, see the move as a politically driven action that could undermine public health guidance. Kiki Freedman, CEO of telehealth abortion provider Hey Jane, criticized the review, calling it evidence of "politically motivated attacks" fueled by “junk science.”

Impact of Restrictions Could Be Severe

In the post-Roe v. Wade legal landscape, at least 16 states have eliminated nearly all avenues for legal abortion. Despite these changes, medication abortion has remained accessible in many areas due to shield laws and telehealth services.

Advocates warn that altering access to mifepristone—especially through narrowing the usage window or restricting telehealth—could sharply limit reproductive care for thousands who rely on remote treatment.

Danika Severino Wynn, Vice President of Care and Access for Planned Parenthood Federation of America, said that mifepristone has been a vital resource for patients for 25 years. She added that telehealth allows access to care for those who might not otherwise receive it, making a significant difference in their lives.

History and Effectiveness of Mifepristone

The FDA first authorized the use of mifepristone in 2000, initially approving it for use within the first seven weeks of pregnancy. This guideline was extended to 10 weeks in 2016, aligning more closely with World Health Organization guidance suggesting usage up to 12 weeks.

Data from the CDC shows a steady rise in the use of medication abortion, up from 19% in 2011 to 57% in 2022. The increase reflects shifts in accessibility and medical guidance, as well as growing reliance on telehealth platforms.

A 2015 systematic review by researchers at the University of California, Davis, found the mifepristone-misoprostol combination to be nearly 97% effective when used as directed.

Future Uncertain as Review Gets Underway

In the meantime, Kennedy’s call for a “complete review” signals that changes may be considered once new data is assessed. However, he has made no guarantee of updated policy or regulatory actions following the conclusion of the review.

A generic version of mifepristone was approved by the FDA in 2019, further contributing to its widespread availability. That access could hang in the balance, depending on the conclusions and implications of the upcoming FDA evaluation.

For now, the agency is expected to gather updated data and weigh the competing health and political priorities surrounding mifepristone’s future. The review's findings may reshape the contours of abortion access for millions of Americans in the months ahead.